Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 2,000 shares, a growth of 139.2% from the August 15th total of 836 shares. Based on an average trading volume of 54,704 shares, the days-to-cover ratio is presently 0.0 days.
Revolution Medicines Trading Up 2.1%
Revolution Medicines stock traded up $0.23 during mid-day trading on Friday, hitting $11.29. 14,919 shares of the company’s stock traded hands, compared to its average volume of 108,598. The firm has a 50 day simple moving average of $10.61 and a two-hundred day simple moving average of $6.63. Revolution Medicines has a fifty-two week low of $0.22 and a fifty-two week high of $13.44.
About Revolution Medicines
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
See Also
- Five stocks we like better than Revolution Medicines
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
